Reproducibility of results in preclinical studies: A perspective from the bone field

Journal of Bone and Mineral Research

Volumn 29, Issue 10, 2014, Pages 2131-2140

  Manolagas, Stavros C ^a   Kronenberg, Henry M ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bone histomorphometry; Bone QCT MICROCT; Genetic animal models

Indexed keywords

ANIMAL EXPERIMENT; BONE METABOLISM; CORTICAL BONE; MEDICAL RESEARCH; MINERAL METABOLISM; MORPHOMETRICS; PRACTICE GUIDELINE; PUBLICATION; QUALITY CONTROL; REPRODUCIBILITY; REVIEW; SCIENTIFIC LITERATURE; STUDY DESIGN; ANIMAL; BONE; DISEASE MODEL; HUMAN; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; PHYSIOLOGY; UNITED STATES;

ANIMALS; BONE AND BONES; DISEASE MODELS, ANIMAL; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; UNITED STATES;

EID: 84907611779     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2293     Document Type: Review

References (43)

1. Collins FS, Tabak LA. Policy, NIH plans to enhance reproducibility. Nature. 2014;505:612-3.
2. Announcement: Reducing our irreproducibility. Nature. 2013 Apr 25;496:398. DOI:10.1038/496398a. Available from: http://www.nature.com/news/announcement-reducing-our-irreproducibility-1.12852.
3. McNutt M. Reproducibility. Science. 2014;343:229.
4. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2:e124.
5. Ioannidis JP, Trikalinos TA. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. J Clin Epidemiol. 2005;58:543-549.
6. Kilkenny C, Parsons N, Kadyszewski E, et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One. 2009;4:e7824.
7. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.
8. Baker D, Lidster K, Sottomayor A, Amor S. Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies. PLoS Biol. 2014;12:e1001756.
9. Hess KR. Statistical design considerations in animal studies published recently in cancer research. Cancer Res. 2011;71:625.
10. Sena E, van der Worp HB, Howells D, MacleodM. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci. 2007;30:433-9.
11. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006;296:1731-2.
12. Nuzzo R. Scientific method: statistical errors. Nature. 2014;506:150-2.
13. Number crunch. Nature. 2014;506:131-2.
14. Krzywinski M, Altman N. Points of significance: importance of being uncertain. Nat Methods. 2013;10:809-10.
15. Krzywinski M, Altman N. Significance. P values and t-tests. Nat Methods. 2013;10:1041-2.
16. Matters of significance. Nat Methods. 2013;10:805.
17. Lambdin C. Significance tests as sorcery: science is empirical-significant tests are not. Theory Psychol. 2012;22:67-690.
18. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187-91.
19. Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383:156-65.
20. Ioannidis JP, Greenland S, Hlatky MA, et al. Increasing value and reducing waste in research design, conduct, and analysis. Lancet. 2014;383:166-75.
21. Al-Shahi SR, Beller E, Kagan J, et al. Increasing value and reducing waste in biomedical research regulation and management. Lancet. 2014;383:176-85.
22. Chan AW, Song F, Vickers A, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383:257-66.
23. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. Lancet. 2014;383:267-76.
24. Chwe MS-Y. Scientific pride and prejudice. New York Times. 2014 Jan 31:Sunday Review. Available from:http://www.nytimes.com/2014/02/02/opinion/sunday/scientific-pride-and-prejudice.html?-r=0.
25. Unreliable research: trouble at the lab. The Economist. 2013 Oct 19. Available from;http://www.economist.com/news/briefing/21588057-scientists-think-science-self-correcting-alarming-degree-it-not-trouble.
26. Boyle WJ, Kung Y, Lacey DL, et al. Osteoprotegerin ligand (OPGL) is required for murine osteoclastogenesis. Bone. 1998;23:S189.
27. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157:435-48.
28. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
29. Tam CS, Heersche JNM, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982;110:506-12.
30. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
31. Wronski TJ, Yen C-F, Qi H, Dann LM. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology. 1993;132:823-31.
32. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216-26.
33. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-15.
34. Andrews N. Skeletal regulation of glucose metabolism: challenges in translation from mouse to man. IBMS Bonekey. 2013; 22 May;10:353. DOI:10.1038/bonekey.2013.87.
35. Qian J, Colbert MC, Witte D, et al. Midgestational lethality in mice lacking the parathyroid hormone (PTH)/PTH-related peptide receptor is associated with abrupt cardiomyocyte death. Endocrinology. 2003;144:1053-61.
36. Lanske B, Karaplis AC, Lee K, et al. PTH/PTHrP receptor in early development and Indian hedgehog- regulated bone growth. Science. 1996;273:663-6.
37. Echeverri CJ, Beachy PA, Baum B, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods. 2006;3:777-9.
38. Fu Y, Foden JA, Khayter C, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31:822-6.
39. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
40. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28:2-17.
41. Weinstein RS. Understanding bone histomorphometry: sampling, evaluation, and interpretation. In: Orwoll ES, editor. Atlas of osteoporosis. Philadelphia: Springer; p. 13-9. 2009.
42. Iida-Klein A, Lu SS, Yokoyama K, Dempster DW, Nieves JW, Lindsay R. Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivo. J Clin Densitom. 2003;6:25-33.
43. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468-86.